PL432883A1 - Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu - Google Patents

Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu

Info

Publication number
PL432883A1
PL432883A1 PL432883A PL43288320A PL432883A1 PL 432883 A1 PL432883 A1 PL 432883A1 PL 432883 A PL432883 A PL 432883A PL 43288320 A PL43288320 A PL 43288320A PL 432883 A1 PL432883 A1 PL 432883A1
Authority
PL
Poland
Prior art keywords
rna
mrna
applications
synthesizing
end cap
Prior art date
Application number
PL432883A
Other languages
English (en)
Other versions
PL248416B1 (pl
Inventor
Marcin WARMIŃSKI
Paweł SIKORSKI
Joanna Kowalska
Jacek Jemielity
Original Assignee
Uniwersytet Warszawski
Explorna Therapeutics Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Warszawski, Explorna Therapeutics Spółka Z Ograniczoną Odpowiedzialnością filed Critical Uniwersytet Warszawski
Priority to PL432883A priority Critical patent/PL248416B1/pl
Priority to US17/798,099 priority patent/US12606590B2/en
Priority to EP21754142.4A priority patent/EP4103577B1/en
Priority to CA3167570A priority patent/CA3167570A1/en
Priority to AU2021219563A priority patent/AU2021219563A1/en
Priority to KR1020227030072A priority patent/KR20220163359A/ko
Priority to JP2022548990A priority patent/JP7805938B2/ja
Priority to PCT/PL2021/050007 priority patent/WO2021162567A1/en
Publication of PL432883A1 publication Critical patent/PL432883A1/pl
Priority to JP2025162162A priority patent/JP2026012182A/ja
Publication of PL248416B1 publication Critical patent/PL248416B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Wynalazek dotyczy nowych analogów kapu końca 5' mRNA, cząsteczek RNA je zawierających, ich zastosowań i sposobów ich syntezy in vitro, jak również sposobu syntezy białka lub peptydu in vitro lub w hodowlach komórkowych, który to sposób obejmuje translację cząsteczki RNA.
PL432883A 2020-02-12 2020-02-12 Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu PL248416B1 (pl)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PL432883A PL248416B1 (pl) 2020-02-12 2020-02-12 Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
US17/798,099 US12606590B2 (en) 2020-02-12 2021-02-12 MRNA 5′-end cap analogs, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule or peptide
EP21754142.4A EP4103577B1 (en) 2020-02-12 2021-02-12 Novel mrna 5'-end cap analogs, rna molecule incorporating the same, uses thereof and method of synthesizing rna molecule or peptide
CA3167570A CA3167570A1 (en) 2020-02-12 2021-02-12 Novel mrna 5'-end cap analogs, rna molecule incorporating the same, uses thereof and method of synthesizing rna molecule or peptide
AU2021219563A AU2021219563A1 (en) 2020-02-12 2021-02-12 Novel mRNA 5'-end cap analogs, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule or peptide
KR1020227030072A KR20220163359A (ko) 2020-02-12 2021-02-12 신규 mRNA 5'-말단 캡 유사체, 이를 혼입한 RNA 분자, 이의 용도 및 RNA 분자 또는 펩티드의 합성 방법
JP2022548990A JP7805938B2 (ja) 2020-02-12 2021-02-12 新規ｍＲＮＡ５’－末端キャップ類似体、それを組み込んだＲＮＡ分子、それらの使用、及びＲＮＡ分子又はペプチドを合成する方法
PCT/PL2021/050007 WO2021162567A1 (en) 2020-02-12 2021-02-12 Novel mrna 5'-end cap analogs, rna molecule incorporating the same, uses thereof and method of synthesizing rna molecule or peptide
JP2025162162A JP2026012182A (ja) 2020-02-12 2025-09-29 新規ｍＲＮＡ５’－末端キャップ類似体、それを組み込んだＲＮＡ分子、それらの使用、及びＲＮＡ分子又はペプチドを合成する方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL432883A PL248416B1 (pl) 2020-02-12 2020-02-12 Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu

Publications (2)

Publication Number Publication Date
PL432883A1 true PL432883A1 (pl) 2021-08-16
PL248416B1 PL248416B1 (pl) 2025-12-08

Family

ID=77292947

Family Applications (1)

Application Number Title Priority Date Filing Date
PL432883A PL248416B1 (pl) 2020-02-12 2020-02-12 Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu

Country Status (8)

Country Link
US (1) US12606590B2 (pl)
EP (1) EP4103577B1 (pl)
JP (2) JP7805938B2 (pl)
KR (1) KR20220163359A (pl)
AU (1) AU2021219563A1 (pl)
CA (1) CA3167570A1 (pl)
PL (1) PL248416B1 (pl)
WO (1) WO2021162567A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120842296A (zh) 2015-09-21 2025-10-28 垂林克生物技术有限公司 用于合成5’-加帽rna的组合物和方法
PL432884A1 (pl) * 2020-02-12 2021-08-16 Uniwersytet Warszawski Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
KR20230034333A (ko) 2020-07-02 2023-03-09 라이프 테크놀로지스 코포레이션 트리뉴클레오티드 캡 유사체, 제조 및 이의 용도
EP4208549A4 (en) 2020-09-04 2025-04-16 Verve Therapeutics, Inc. Compositions and methods for capping RNAs
JP2025507894A (ja) * 2022-03-01 2025-03-21 ヴァーヴ・セラピューティクス，インコーポレーテッド Ｒｎａをキャッピングするための組成物及び方法
CN120129688A (zh) * 2022-08-26 2025-06-10 垂林克生物技术有限公司 用于制备高度纯化的5′-加帽寡核苷酸的高效方法
WO2024075022A2 (en) 2022-10-04 2024-04-11 BioNTech SE Rna constructs and uses thereof
EP4464713A1 (en) 2023-05-18 2024-11-20 Siec Badawcza Lukasiewicz - PORT Polski Osrodek Rozwoju Technologii Circular rna analogs, preparation and application thereof
WO2025054401A2 (en) * 2023-09-06 2025-03-13 Trilink Biotechnologies, Llc Cap analogs and methods of use thereof
WO2025147660A2 (en) 2024-01-04 2025-07-10 Trilink Biotechnologies, Llc Modified rna for increasing protein expression
EP4606900A1 (en) * 2024-02-21 2025-08-27 ExploRNA Therapeutics Sp. z o. o. Modified rna for the treatment of cfdna-associated diseases
WO2025187713A1 (en) * 2024-03-07 2025-09-12 Eisai R&D Management Co., Ltd. Polynucleotide and producing method thereof
WO2026010855A1 (en) 2024-07-02 2026-01-08 Trilink Biotechnologies, Llc Modified rna for increasing protein expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120842296A (zh) * 2015-09-21 2025-10-28 垂林克生物技术有限公司 用于合成5’-加帽rna的组合物和方法
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
KR20200143391A (ko) 2018-03-15 2020-12-23 비온테크 알엔에이 파마슈티컬스 게엠베하 5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용
PL432884A1 (pl) 2020-02-12 2021-08-16 Uniwersytet Warszawski Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu

Also Published As

Publication number Publication date
EP4103577B1 (en) 2026-05-06
US20230130423A1 (en) 2023-04-27
PL248416B1 (pl) 2025-12-08
JP2023513764A (ja) 2023-04-03
WO2021162567A1 (en) 2021-08-19
EP4103577A4 (en) 2024-03-06
CA3167570A1 (en) 2021-08-19
EP4103577A1 (en) 2022-12-21
KR20220163359A (ko) 2022-12-09
JP2026012182A (ja) 2026-01-23
US12606590B2 (en) 2026-04-21
AU2021219563A1 (en) 2022-09-08
JP7805938B2 (ja) 2026-01-26

Similar Documents

Publication Publication Date Title
PL432884A1 (pl) Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
PL432883A1 (pl) Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
WO2022271965A3 (en) Compositions and methods for improved protein translation from recombinant circular rnas
CL2021002742A1 (es) Una proteína crispr de prevotella y francisella 1 (cpf1) aislada de francisella tularensis; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004)
BR112021025359A2 (pt) Composições de proteína anti-vegf e métodos para a produção das mesmas
MX2016008551A (es) Moleculas artificiales de acido nucleico.
PE20140867A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso
PL417980A1 (pl) Nowe fosfotriazolowe analogi kapu końca 5' mRNA, kompozycja je zawierająca, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA, białka i peptydu
CO5601037A2 (es) Anticuerpos anti-a beta y sus usos
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
PE20090483A1 (es) Vectores para la expresion multiple de genes
EP1871426A4 (en) RNA MOLECULES WITH LOW ACTIVATION
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
UY31875A (es) Novedosos genes involucrados en la biosíntesis
MX2022015376A (es) Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
MX2023001083A (es) Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
CY1120078T1 (el) Διαδικασια παραγωγης και επεξεργασιας του παραγοντα viii και τα παραγωγα του
EA202091349A1 (ru) Способы культивирования клеток
GEAP202516650A (en) Stabilized pre-fusion hmpv fusion proteins
BRPI0410562B8 (pt) proteína de veículo e seu método de produção em uma planta, ácido nucleico isolado, vetor de expressão e célula hospedeira
WO2018132821A3 (en) Elastomeric proteins
MX2022010985A (es) Expresión de proteínas sars-cov, constructos de ácido nucleico, proteínas tipo virus (vlp) y métodos relevantes a los mismos.
FI20115310L (fi) Proteaasientsyymi ja sen käytöt
ECSP077240A (es) Variantes mejoradas de la aprotinina
EA200800253A1 (ru) Бессывороточная культуральная среда для получения рекомбинантных гонадотропинов